David Sher, MD, discusses efficacy outcomes with daily adaptive radiotherapy with 1-mm planning target volume margins in patients with head and neck squamous cell carcinoma.
David Sher, MD
Advertisement
Articles by David Sher, MD
David Sher, MD, radiation oncologist, UT Southwestern Medical Center, provides an update on and the basis for ASTRO's Multidisciplinary Head and Neck Cancer Guideline.
Advertisement
Latest Updated Articles
Dr. Sher on ASTRO's Head and Neck Cancer Guideline UpdateMarch 24th 2016
Advertisement
Advertisement
Trending on OncLive
1
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
2
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
5